PDCD1 and cancer: Several therapeutic Abs that inhibit either PD-1 or PD-1L have been tested in clinical trials and some of them (namely, pembrolizumab, nivolumab, atezolizumab, avelumab, durvalumab, and cemiplimab) are FDA-approved for different types of cancer.